Cagrilintide
Cagrilintide (Novo Nordisk development code AM833) is a long-acting, injectable analogue of the peptide hormone amylin that also engages calcitonin receptors, placing it in the amylin-receptor-agonist class. It has drawn substantial research interest as a candidate studied for appetite regulation and body-weight management, both on its own and in fixed-dose combination with the GLP-1 receptor agonist semaglutide (a pairing known as CagriSema). Its appeal lies in acting through a satiety pathway that is complementary to, rather than overlapping with, the incretin (GLP-1) mechanism. It remains an investigational compound and is not an approved medicine.
Side effects & risks
The most commonly reported adverse effects in trials of amylin-analogue and combination therapies are gastrointestinal, including nausea, vomiting, diarrhea, constipation, and reduced appetite, which are often most pronounced during dose escalation. Injection-site reactions have also been reported. As with the broader GLP-1/amylin weight-management class, there are theoretical and monitored concerns around gallbladder-related events, pancreatitis, and effects on heart rate, and the long-term safety profile of cagrilintide specifically is still being characterized. Because amylin-receptor agonists act partly through the calcitonin receptor, thyroid-related monitoring considerations discussed for related agents may be relevant, though human data specific to cagrilintide are limited. It is investigational, so its contraindications and drug interactions are not fully established, and it has not been evaluated for safety in pregnancy, breastfeeding, or many chronic-disease populations. Research-grade material carries additional risks of impurity, mislabeling, and dosing error. Anyone considering it should consult a qualified clinician; this information is not medical advice and no safe self-administration protocol is implied.
Latest studies
Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?
This hypothesis paper proposes that amylin-based therapies such as cagrilintide may activate the renin-angiotensin system, and that combining them with blood-pressure medications could redirect that activation toward a protective pathway. The authors outline preclinical and clinical studies to test the idea.
Co-agonism of GLP-1R and CTR/AMYR in the lateral dorsal tegmental nucleus produces additive effects on homeostatic and motivated feeding.
A rodent brain-mapping study found that GLP-1 and amylin receptor agonists act on largely separate neuron populations in a brainstem region called the LDTg, and hitting both receptor systems at once suppressed feeding and food motivation more than either alone — mechanistic support for combinations like CagriSema (cagrilintide plus semaglutide).
Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials.
This systematic review pooled seven randomized trials covering 8,069 people to compare CagriSema, a fixed-dose combination of cagrilintide and semaglutide, against placebo and against each component alone. Pooled weight loss with the combination was about 7.6 kg greater than semaglutide alone, 9.2 kg greater than cagrilintide alone, and 14.0 kg greater than placebo. Side effects were mostly gastrointestinal and injection-site reactions, with no signal of more serious adverse events.
Community discussion
Community-reported · not verified
These are synthesised observations from public forum discussions. They are community-reported, not clinically verified, and should not inform any health decision. The peptide does not cure, treat, or prevent any condition based on these reports.
“Currently on 120mg per week, twice weekly injection IM. Would daily subq help with haematocrit? Its going up as well as my oestradiol, my body fat is about 24% and taking reta, ghk-cu, 5 amino 1mq as well as Cagrilintide twice a week. Training 5-6 times a week weights and clean diet 1800 call and 15”
A TRT user on 120mg weekly testosterone asks whether switching to daily subcutaneous injections would help manage rising haematocrit and oestradiol, while also running retatrutide, cagrilintide, GHK-Cu, and 5-Amino-1MQ alongside training and a calorie deficit.
“Currently on 120mg per week, twice weekly injection IM. Would daily subq help with haematocrit? Its going up as well as my oestradiol, my body fat is about 24% and taking reta, ghk-cu, 5 amino 1mq as well as Cagrilintide twice a week. Training 5-6 times a week weights and clean diet 1800 call and 15”
A crosspost in an Australian TRT subreddit: the poster asks whether daily subcutaneous testosterone dosing would help manage climbing haematocrit and oestradiol while stacking retatrutide, cagrilintide, GHK-Cu, and 5-Amino-1MQ with weight training and a strict diet.
Reported protocols (with caveats)
In the published clinical program, cagrilintide has been reported as a once-weekly subcutaneous injection, typically using a dose-escalation schedule to improve tolerability, with trial doses studied across a range up to roughly 2.4 mg weekly and higher exploratory levels in dose-finding work. It has most often been reported in combination with semaglutide (CagriSema), reflecting the paired-mechanism rationale. Any doses, routes, or frequencies described here reflect reported research-context use only and are provided for informational purposes, not as a protocol to follow. Cagrilintide is sold and discussed in some circles as a research chemical labeled for research use only, and such material is not manufactured to pharmaceutical quality standards. Nothing here is recommended; individuals should not self-source or self-administer an investigational compound.